Compare DV & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DV | NRIX |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | DV | NRIX |
|---|---|---|
| Price | $10.99 | $19.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $16.56 | ★ $26.77 |
| AVG Volume (30 Days) | ★ 2.3M | 1.9M |
| Earning Date | 11-07-2025 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $733,324,000.00 | $83,687,000.00 |
| Revenue This Year | $17.93 | $58.38 |
| Revenue Next Year | $10.74 | N/A |
| P/E Ratio | $41.60 | ★ N/A |
| Revenue Growth | 14.86 | ★ 48.32 |
| 52 Week Low | $7.64 | $8.18 |
| 52 Week High | $23.11 | $22.50 |
| Indicator | DV | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 66.53 |
| Support Level | $10.83 | $19.02 |
| Resistance Level | $11.26 | $22.50 |
| Average True Range (ATR) | 0.27 | 1.18 |
| MACD | 0.10 | 0.10 |
| Stochastic Oscillator | 73.85 | 52.01 |
DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.